“Our innovative pipeline, expertise in biomarkers, external collaborations and history of success with novel therapeutics continue to make Janssen a global leader in the treatment of immunological diseases.”
Mark Curran, Ph.D.
Vice President, Systems Pharmacology & Biomarkers, Immunology, Janssen Research & Development
More than two decades ago, our scientists pioneered the use of antibodies to tumor necrosis factor (TNF)-alpha to treat chronic, immune-mediated diseases. What followed was a long line of firsts in biotechnology, starting with the development and approval of the first anti-TNF-alpha treatment. We work to continue to achieve success in the discovery of new, promising biologic and oral therapeutics, as well as co-diagnostic solutions. As unmet patient needs persist, we look to these next-generation treatments to improve the standard of care.
Supporting these efforts, our extensive biomarker discovery program compiles valuable information that may ultimately provide healthcare professionals with the tools needed to consistently prescribe the most appropriate treatment to each patient—the first time. Through cutting-edge technologies, our scientists are able to track disease progression and treatment efficacy in pre-clinical studies, providing us with a better understanding of disease mechanisms, longer-term disease impact and the effect of therapy. Computer-based research also offers insight into disease pathogenesis and potential targets for therapeutic intervention, thus accelerating efforts to bring medicines to market.
Our focus on understanding disease at the molecular level is key to the discovery of new targets that drive inflammation and autoimmune processes, and our early work on understanding disease triggers may enable entirely new approaches to treating and potentially preventing disease.